ClinicalTrials.gg
Sign In

BiosimilarDrug

BP102 clinical trials

Also written BP102.

A product of Bevacizumab; its studies count on that page too.

studies test it
12
open now
6
in phase 3
3
first study started
2018

Keep track of what changes. Save the BP102 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

BP102
5

Studies by the year they started

12 studies that test it; most in 2018 (3)

Studies that test BP102, by start year
YearStudies
20183
20211
20222
20231
20242
20253

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
9
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it.

Colorectal Neoplasms
4
Lung Neoplasms
2
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Triple Negative Breast Neoplasms
1
Uterine Cervical Neoplasms
1

Who runs them

Industry 7 · Other 5

Jiangsu HengRui Medicine Co., Ltd. (4) · Fudan University (3) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · West China Hospital (1) · Shandong Suncadia Medicine Co., Ltd. (1)

Often tested with

Tested in the same studies.

Camrelizumab (3) · HRS-2189 (1) · Adebrelimab (1) · SHR-1701 (1) · Zeprumetostat (1) · Anti-CTLA-4 Monoclonal Antibody SHR-8068 (1) · Trastuzumab rezetecan (1) · Famitinib (1)

Studies

Open first, then newest update. How each study uses BP102 is read from its arms, and is right about nine times in ten.

Testing it · 12

Given in every arm · 2 — BP102 is usual care beside what is tested